Dante Labs, also known as Dante Genomics, was founded in 2016 by Andrea Riposati, its CEO, and Mattia Capulli, the chief scientific officer in L’Aquila, Italy. It is a top genomics and precision medicine organization dedicated to accelerating science to help deliver better healthcare.

According to Riposati, their mission is to use whole genome sequencing technology plus variant interpretation to make informed decisions about clients’ health and their future.

On 1st November 2022, Dante Labs partnered with Longenesis, a biotechnology startup, to deliver whole genome sequencing to over 10,000 existing participants in a Longenesis study.

Longenesis is a SaaS organization backed up by Insilico medicine and other tech leaders to unlock a healthy future for people globally. It has developed an end-to-end intuitive toolkit for patient-centric engagement and information discovery.

Engage and Curator are their flagship products that are highly secure and made to help patients control their personal information while sharing it with researchers and doctors globally.

Dante Labs’ subsequent genomic reports and whole genome sequencing are essential health tools that can offer individuals and physicians information about genetic carrier information, dietary choices, plus predisposition to genetic diseases.

Longenesis has a platform that provides a dynamic, digital, and secure engagement tool that encourages its participants’ network to explore and begin using Dante labs’ genomic solutions. This ensures the platform has ethical and legal compliance and offers streamlined consent for approximately 20,000 women worldwide.

Traditionally, women in the Mediterranean and Baltic regions could not easily get DNA tests because of high costs, inadequate practitioners, and lack of resources and services.

Longenesis will use its digital engagement platform to offer its participants different offerings from Dante Labs. Some of those offerings include at-home WGS blood collection kits without using needles and extra women’s health reports without re-testing.

Riposati said that partnerships like these allow them to offer more individuals in different regions personalized genomic solutions using personalized data.